摘 要: 乳腺癌是全球最常见的导致女性死亡的癌症之一。目前, 除手术治疗外, 化疗仍是乳腺癌全身治疗的重要手段。但预后差、总生存期短、复发快严重影响着乳腺癌的治疗效果。随着信号通路、细胞凋亡等分子生物学在肿瘤研究中的深入, 新型靶向抗肿瘤药物已成为当前抗癌研究的热点, 并在乳腺癌的治疗中取得了一定的进展。近年来研究发现乙酰胆碱受体与人类多种疾病密切相关, 尤其是其参与了多种肿瘤的发生、发展。因此, 乙酰胆碱受体的特异性拮抗剂α-芋螺毒素可能成为新颖的乳腺癌靶向治疗药物。

Abstract: Breast cancer is one of the most common cancers that lead to death in women worldwide. At present, chemotherapy is still an important means of systemic treatment of breast cancer besides the surgical treatment. But poor prognosis, short survival and fast recurrence affect the therapeutic effect. With the development of the signaling pathways and cell apoptosis in the tumor research, targeted therapy against main signaling pathways of breast carcinogenesis has become a focus of anti-tumor research, and some progress has been made in the treatment of breast cancer. In recent years, studies found that acetylcholine receptors are correlated with the occurrence and development of many diseases, especially tumors. Therefore, alpha-conotoxins, as a specific antagonist of the acetylcholine receptor, may become a novel targeted therapy drug for breast cancer.